- Home
- GPRK vs PRLD Comparison
GPRK vs PRLD Comparison
Compare GPRK & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPRK | PRLD |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 649.0M | 529.1M |
| IPO Year | 2009 | 2020 |
Fundamental Metrics
Financial Performance| Metric | GPRK | PRLD |
|---|---|---|
| Price | $11.90 | $3.57 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $10.85 | $9.20 |
| AVG Volume (30 Days) | ★ 720.1K | 441.7K |
| Earning Date | 11-04-2026 | 11-11-2026 |
| Dividend Yield | ★ 0.77% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $12,140,000.00 |
| Revenue This Year | $19.28 | $258.83 |
| Revenue Next Year | $17.77 | N/A |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $5.75 | $1.16 |
| 52 Week High | $13.13 | $6.83 |
Technical Indicators
Market Signals| Indicator | GPRK | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 62.00 | 30.79 |
| Support Level | $8.98 | $3.48 |
| Resistance Level | $13.13 | $4.10 |
| Average True Range (ATR) | 0.40 | 0.25 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 85.05 | 12.36 |
Price Performance
Historical ComparisonAbout GPRK Geopark Ltd
GeoPark Ltd is an independent energy company. Its diversified portfolio of assets consist of Llanos 34 Block in Colombia, CPO-5 Block, Llanos 86, Llanos 87, Llanos 104, Llanos 123, and Llanos 124 Blocks in the Llanos Basin. Its segments include Colombia, Argentina, Brazil and Ecuador, with the majority of the revenue derived from Colombia. It derives revenue from Sale of crude oil, Sale of purchased crude oil, and Sale of gas.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.